Repeated courses of escalating doses of Nivolumab in refractory Hodgkin lymphoma with recurrent relapses post allografting: A safe and effective treatment approach
For patients with Hodgkin Lymphoma (HL) who experience relapse post allogeneic stem cell transplantation, limited treatment options exist, and the ultimate outcome is poor. Recently, the programmed cell death protein-1 (PD-1) inhibitors have shown remarkable efficacy in patients with refractory/rel...
Main Authors: | Panayotis Kaloyannidis, Eshrak Al Shaibani, Asif Moinnudin, Khalid Al Anezi, Hani Al Hashmi |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2021-03-01
|
Series: | Hematology Reports |
Subjects: | |
Online Access: | https://www.pagepress.org/journals/index.php/hr/article/view/8780 |
Similar Items
-
Relapse of Hodgkin lymphoma after autologous hematopoietic cell transplantation: A current management perspective
by: Madiha Iqbal, et al.
Published: (2021-06-01) -
LYMPHOID NEOPLASMS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION. THE CASE OF SECONDARY HODGKIN’S LYMPHOMA, DIFFERENTIAL DIAGNOSIS WITH POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE
by: Yu. V. Skvortsova, et al.
Published: (2017-06-01) -
Outcomes of allogeneic hematopoietic stem cell transplantation for lymphomas: a single-institution experience
by: Mira Romany Massoud, et al. -
De Novo Psoriasis Vulgaris Diagnosed after Nivolumab Treatment for Refractory Hodgkin’s Lymphoma, Completely Resolved after Autologous Hematopoietic Stem Cell Transplantation
by: Panayotis Kaloyannidis, et al.
Published: (2018-01-01) -
Nivolumab in relapsed/refractory Hodgkin Lymphoma patients, single center experiences
by: Ramazan Acar, et al.
Published: (2020-12-01)